|
|
|
|
February 2010 Briefing - Nephrology
Here are what the editors at HealthDay consider to be the most important developments in Nephrology for February 2010.This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most...
|
|
|
Revised Exjade Prescribing Information
Novartis Oncology has revised the prescribing information (PI) for Exjade (deferasirox) to include a Boxed Warning stating that the medication may cause hepatic or renal impairment, including failure and/or gastrointestinal hemorrhage.Fatal reactions...
|
|
|
FDA Announces Boxed Warning for Exjade
ROCKVILLE, Md., Feb.18, 2010--Novartis Oncology and FDA notified healthcare professionals about recent changes in the Prescribing Information (PI) for Exjade, indicated for the treatment of chronic iron overload due to blood transfusions in patients 2...
|
|
|
Novartis Updates Exjade Prescribing Information
Novartis Oncology has alerted health care professionals about changes in the prescribing information for Exjade (deferasirox), a treatment for chronic iron overload due to blood transfusions in patients 2 years of age and older, acc Novartis Updates ...
|
|
|
Novartis Updates Exjade Prescribing Information
MONDAY, Feb.22 (HealthDay News) -- Novartis Oncology has alerted health care professionals about changes in the prescribing information for Exjade (deferasirox), a treatment for chronic iron overload due to blood transfusions in patients 2 years of age...
|
|
|
Boxed Warning Issued on Medication for Blood Transfusion Iron Overload
Novartis Oncology and FDA notified healthcare professionals this week about recent changes in the prescribing information (PI) for Exjade, a medication indicated for the treatment of chronic iron overload due to blood transfusions in patients age 2 and...
|
|
|
FDA ups safety warning on iron drug
A boxed warning highlighting serious safety concerns, including reported deaths, with the use of Novartis AG's Exjade drug to remove excess iron from the blood, has been added to the medicine's label, the US Food and Drug Administration said.In a...
|
|
|
2/18/10 - FDA approves boxed warning for Exjade
The U.S.Food and Drug Administration says it has approved a boxed warning for Exjade, used to treat chronic iron overload due to blood transfusions. The FDA said Exjade (deferasirox) is indicated for use in patients 2 years of age and older.
|
|
|
FDA approves boxed warning for Exjade
The U.S.Food and Drug Administration says it has approved a boxed warning for Exjade, used to treat chronic iron overload due to blood transfusions. The FDA said Exjade (deferasirox) is indicated for use in patients 2 years of age and older.
|
|
|
FDA Raises Safety Warning On Novartis Iron Drug
A boxed warning highlighting serious safety concerns, including reported deaths, with the use of Novartis AG's Exjade drug to remove excess iron from the blood, has been added to the medicine's label, the U.S.Food and Drug Administration said. In a...
|
|
|
FDA: Boxed warning added to label of Novartis' Exjade
In a notice posted to its website, the FDA stated on Thursday that the label for Novartis' Exjade (deferasirox) has been adjusted and now includes a boxed warning stating that the oral iron chelator may cause kidney and liver impairment or failure, and...
|
|
|
Novartis' iron drug Exjade will carry black-box warning
The FDA announced that Novartis' iron treatment Exjade will come with a black-bo Novartis' iron drug Exjade will carry black-box warning.
|
|
|
FDA Requests Boxed Warning on Exjade Labeling
Novartis Oncology will be adding a new boxed warning to its Exjade drug to warn FDA Requests Boxed Warning on Exjade Labeling.
|
|
|
Oncology Drug Gets Black Box Warning
By Cole Petrochko, Staff Writer, MedPage Today Published: February 18, 2010 WASHINGTON -- A black box warning -- which includes cautions about potentially fatal renal, hepatic, and gastrointestinal damage -- has been added to the labeling for the oncology drug...
|
|
|
UPDATE 2-FDA raises safety warning on Novartis iron drug
* Warns drug may cause kidney, liver failure * Agency says deaths reported with Exjade use * Says more likely to affect high risk patients (Adds Novartis comment) NEW YORK, Feb 18 (Reuters) - A boxed warning highlighting serious safety concerns, including...
|
|
|
FDA raises safety warning on Novartis iron drug
NEW YORK - A boxed warning highlighting serious safety concerns, including reported deaths, with the use of Novartis AG's Exjade drug to remove excess iron from the blood, has been added to the medicine's label, the U.S.Food and Drug Administration...
|
|
|
FDA raises safety warning on Novartis iron drug
NEW YORK (Reuters) - A boxed warning highlighting serious safety concerns, including reported deaths, with the use of Novartis AG's Exjade drug to remove excess iron from the blood, has been added to the medicine's label, the U.S.Food and Drug...
|
|
|
FDA raises safety warning on Novartis iron drug
NEW YORK (Reuters) - A boxed warning highlighting serious safety concerns, including reported deaths, with the use of Novartis AG's Exjade drug to remove excess iron from the blood, has been added to the medicine's label, the U.S.Food and Drug...
|
|
|
UPDATE 1-FDA raises safety warning on Novartis iron drug
* Warns drug may cause kidney, liver failure * Agency says deaths reported with Exjade use * Says more likely to affect high risk patients NEW YORK, Feb 18 (Reuters) - A boxed warning highlighting serious safety concerns, including reported deaths, with...
|
|
|
FDA raises safety warning on Novartis iron drug
In a message on its Website, the FDA said the prescribing information for Exjade would now carry a highlighted warning, often called a black box, noting that the drug may cause renal impairment, including kidney failure; hepatic impairment, including...
|
|
|
Exjade (deferasirox): Boxed Warning - Changes to Prescribing Information re: risk of renal impairment/failure,
ROCKVILLE, Md., Feb.18, 2010--Novartis Oncology and FDA notified healthcare professionals about recent changes in the Prescribing Information (PI) for Exjade, indicated for the treatment of chronic iron overload due to blood transfusions in patients 2...
|
|
|
FDA Adds Black Box Warning to Oncology Drug
By Cole Petrochko, Staff Writer, MedPage Today Published: February 18, 2010 WASHINGTON -- A black box warning -- which includes cautions about potentially fatal renal, hepatic, and gastrointestinal damage -- has been added to the labeling for the oncology drug...
|
